Instructions for Ismigen
Ismigen Strucure:
Sublingual tablets 1 tab.
Ismigen active substance:
lyophilized bacterial lysates 50 mg
( Including active components: lysates of bacteria Staphylococcus aureus , Streptococcus pyogenes , Streptococcus viridans , Streptococcus pneumoniae (type TY1 / EQ11, TY2 / EQ22, TY3 / EQ14, TY5 / EQ15, TY8 / EQ23, TY47 / EQ24), Klebsiella pneumoniae , Klebsiella ozaenae , Haemophilus influenzae b , Neisseria catarrhalis - 7 mg; excipient: glycine - 43 mg)
excipients: MCC - 150 mg; calcium hydrogen phosphate dihydrate - 35 mg; colloidal silicon dioxide - 10 mg; magnesium stearate - 3 mg; ammonium glycyrrhizinate - 1.2 mg; mint flavor - 0.8 mg
Ismigen Description of the dosage form:
Tablets are flat-cylindrical with a scored, light cream color, with brown blotches and a faint smell of mint.
Ismigen pharmachologic effect:
Pharmacological action - immunostimulating .
Ismigen Pharmacodynamics:
Combined immunostimulating drug of bacterial origin for sublingual (sublingual) use. It is a polyvalent antigenic complex containing lysates of bacteria - the most common causative agents of respiratory infections. Lysates were included in the drug Ismigen ® , obtained by mechanical disruption of the bacterial cells.
Ismigen has a nonspecific immunostimulating and specific vaccination effect on various links of immunity. Stimulates both local (increases the concentration of secretory IgA) and systemic (cellular and humoral) immunity. Activates phagocytosis, increases the content of lysozyme in saliva, increases the number of immunocompetent cells, increases the concentration of serum IgA, IgG, IgM and reduces the concentration of serum IgE.
Increases the functional activity of macrophages ( including alveolar) and polymorphonuclear leukocytes, which contributes to the destruction of infectious agents.
As a result of treatment with reduced frequency, duration and severity of acute respiratory tract infections; relief and leveling of symptoms such as fever, cough, shortness of breath is observed, the need for antibacterial and anti-inflammatory therapy decreases; in patients with chronic diseases of the respiratory tract, the drug also prevents exacerbations.
Ismigen Indications of the drug:
acute and subacute infections of the upper and lower respiratory tract: bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media, including complications after influenza (treatment as part of combination therapy);
recurrent infections of the upper and lower respiratory tract, chronic bronchitis (prevention of exacerbations).
Ismigen Contraindications:
hypersensitivity to active and / or auxiliary components of the drug;
autoimmune diseases;
pregnancy;
breastfeeding period;
children up to age 3 years.
Application during pregnancy and lactation
Contraindicated.
Ismigen Side effects:
The incidence of side effects is classified according to the WHO recommendations : very often - more than 10%; often - more than 1 and less than 10%; infrequently - more than 0.1 and less than 1%; rarely - more than 0.01 and less than 0.1%; very rarely - less than 0.01%; unknown frequency - cannot be estimated from the available data.
Skin and subcutaneous tissue disorders: very rarely - urticaria, dermatitis, folliculitis; unknown frequency - allergic reactions such as rash, itching and angioedema.
Others: very rarely - inflammation of the salivary gland, acute laryngitis, rhinitis.
If the patient has or aggravates the side effects indicated in the instructions, or the patient noticed any other side effects that are not indicated in the instructions, it is necessary to inform the doctor about this.
Interaction
Ismigen can be used concurrently with other drugs intended for the treatment of acute and chronic respiratory diseases.
Features of the interaction of Ismigen ® with other drugs have not yet been described.
If the patient uses the above or other drugs ( including over-the-counter), consult a doctor before using
Ismigen Method of administration and dosage:
Sublingually , on an empty stomach. The tablet should be kept under the tongue until it is completely dissolved. Sublingual tablets should not be sucked, chewed or swallowed.
Acute and subacute upper and lower respiratory tract infections. 1 table / day until the symptoms of the disease disappear (at least 10 days).
Recurrent infections of the upper and lower respiratory tract, prevention of exacerbations of chronic respiratory diseases. 1 table / day for 10 days. The prophylactic course includes 3 cycles of 10 days with 20-day intervals between them. The prophylactic course should be carried out no more than 1-2 times a year.
If you skip taking the next dose, you should not double it the next time you take it.
If after treatment there is no improvement or symptoms worsen, or new symptoms appear, you should consult your doctor.
The drug should be used only according to the indications, the method of administration and the doses indicated in the instructions.
Ismigen Overdose:
There are no data on cases of overdose.
Ismigen special instructions:
Children from 3 to 6 years old should be supervised by adults while taking each dose until the tablet is completely dissolved in the mouth.
Influence on the ability to drive vehicles, mechanisms. Does not affect.
Release form
Sublingual tablets, 7 mg. 10 tab. in a blister strip made of PVC film and aluminum foil. 1 or 3 blister packs in a cardboard box.
